logo

iStock Rating

D
Details...
Enter Symbol click to research

Allos Therapeutics, Inc. (NASDAQ: ALTH)

Sector: Medical

Current Price : $1.84

52 Week Low
$1.2552 Week High
$1.94
 

ALLOS THER(NSDQ:ALTH)
Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company''s lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.
# Employees: 111
Address: 11080 CIRCLEPOINT ROAD SUITE 200,WESTMINSTER,CO,USA
Phone: 3034266262
Fax: 303-426-4731
Website: http://www.allos.com
Email: investorrelations@allos.com
Sector: Medical
Industry: MED-DRUGS
Executive Officers
Stephen J. Hoffman (Chairman of Board of Directors and Director)
Paul L. Berns (President; Chief Executive Officer and Director)
David C. Clark (Vice President; Finance and Treasurer)
Cecilia Gonzalo (Director)
Jeffrey R. Latts (Director,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 3/31/2012
Next Earnings Date(Expected): 8/13/2012
Mean EPS (Next Qtr): ($0.05)
Mean EPS (Year): ($0.23)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 2
Shares Performance
Period alth Compare to S&P
YTD 25.35 % 12.13 %
4 Weeks -0.56 % -4.03 %
12 Weeks -0.56 % -8.39 %
Shares Information
Analyst Coverage: Y
Avg Volume: 886549
Shares Outstanding: 106M
Market Cap: $0.19B
52 Week High: $1.94
52 Week Low: $1.25
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 alth split by factor of 0.100
Earnings Performance
EPS Growth in Last Quarter: -1,000.00 %
EPS Growth in Last Year: 21.43 %
Sales Growth in Last Quarter: 18.85 %
Sales Growth in Last Quarter: -65.55 %
Financials
Qtr Book Value: $2.91
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 3.410
Home | Login |Research | Earnings | Scans | Charts | Submit Article | Join Blog Network | Advertise | Subscribe to RSS

Terms of Use | Privacy Policy | Copyright 2012 all rights reserved
Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia. Advertisement partners Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.